Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
ATG (Horse), Cyclosporine, Eltrombopag Variant #01 | — | R 618 124 | 180d | — | — | — | — | — |
ATG (Horse), Cyclosporine, Sirolimus Variant #01 | — | R 285 002 | 180d | — | — | — | — | — |
ATG (Rabbit) and Cyclosporine Variant #01 | — | R 78 547 | — | — | — | — | — | — |
ATG (Horse), Cyclosporine, Methylprednisolone Variant #01 | — | R 24 561 | — | — | — | — | — | — |
Cyclosporine monotherapy Variant #03 | — | R 2 156 | — | — | — | — | — | — |
ATG (Horse) and Cyclosporine N/A - secondary systemic drug | — | R 109 | — | — | — | — | — | — |
ATG (Horse), Cyclosporine, G-CSF N/A - secondary systemic drug | — | R 49 | — | — | — | — | — | — |
7 of 7 regimens shown